ProNAi Therapeutics Inc. (NASDAQ:DNAI)’s share price was up 3.1% during mid-day trading on Tuesday . The company traded as high as $2.03 and last traded at $2.01, with a volume of 762,798 shares traded. The stock had previously closed at $1.95.

A number of equities analysts have recently issued reports on DNAI shares. Wedbush reissued an “outperform” rating and set a $36.00 price target on shares of ProNAi Therapeutics in a research report on Friday, May 27th. SunTrust Banks Inc. downgraded ProNAi Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $25.00 to $4.00 in a research report on Monday, June 6th. Jefferies Group downgraded ProNAi Therapeutics from a “buy” rating to a “hold” rating and dropped their price target for the stock from $22.00 to $4.50 in a research report on Monday, June 6th. Finally, Zacks Investment Research downgraded ProNAi Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $17.35.

The company’s market cap is $60.65 million. The firm’s 50 day moving average price is $2.02 and its 200 day moving average price is $5.56.

ProNAi Therapeutics (NASDAQ:DNAI) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.07. On average, analysts expect that ProNAi Therapeutics Inc. will post ($1.33) EPS for the current year.

A hedge fund recently bought a new stake in ProNAi Therapeutics stock. Jennison Associates bought a new position in shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 150,381 shares of the company’s stock, valued at approximately $3,086,000. Jennison Associates owned approximately 0.50% of ProNAi Therapeutics as of its most recent filing with the SEC.

ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.